MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.

[1]  P. Elliott,et al.  Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy: Disease Expression in Relation to Age, Gender, and Long Term Outcome , 2012, Circulation. Cardiovascular genetics.

[2]  C. Fishwick,et al.  Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone , 2012, Cell calcium.

[3]  E. R. Paalberends,et al.  Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function , 2012, Circulation. Heart failure.

[4]  M. Link,et al.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.

[5]  A. Wilde,et al.  Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction , 2011, European journal of heart failure.

[6]  D. Kuster,et al.  Cardiac myosin binding protein C phosphorylation in cardiac disease , 2011, Journal of Muscle Research and Cell Motility.

[7]  V. Álvarez,et al.  Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations. , 2011, Clinical chemistry.

[8]  H. Watkins,et al.  Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. , 2011, Circulation research.

[9]  L. Carrier,et al.  Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. , 2011, Journal of molecular and cellular cardiology.

[10]  D. Mann,et al.  Role of MicroRNAs in Cardiac Remodeling and Heart Failure , 2011, Cardiovascular Drugs and Therapy.

[11]  S. Harris,et al.  In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. , 2011, Circulation research.

[12]  E. Paquet,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[13]  M. Latronico,et al.  microRNAs in hypertrophy and heart failure , 2011, Experimental biology and medicine.

[14]  G. Condorelli,et al.  MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling , 2010, Nature Cell Biology.

[15]  David J Beech,et al.  Pregnenolone Sulphate- and Cholesterol-Regulated TRPM3 Channels Coupled to Vascular Smooth Muscle Secretion and Contraction , 2010, Circulation research.

[16]  E. Olson,et al.  MicroRNA regulatory networks in cardiovascular development. , 2010, Developmental cell.

[17]  Jian-Fu Chen,et al.  MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. , 2009, The Journal of clinical investigation.

[18]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[19]  T. Golub,et al.  MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes , 2009, Molecular and Cellular Biology.

[20]  F. T. ten Cate,et al.  Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.

[21]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[22]  W. Paulus,et al.  Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies , 2007, Proteomics. Clinical applications.

[23]  Stanley Nattel,et al.  Regional and tissue specific transcript signatures of ion channel genes in the non‐diseased human heart , 2007, The Journal of physiology.

[24]  C. Croce,et al.  MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.

[25]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[26]  H. Brinkmeier,et al.  Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains , 2006, BMC Genomics.

[27]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[28]  V. Regitz-Zagrosek,et al.  The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.

[29]  G. Schultz,et al.  Molecular and Functional Characterization of the Melastatin-related Cation Channel TRPM3* , 2003, Journal of Biological Chemistry.

[30]  Shujian Wu,et al.  Expression and Characterization of Human Transient Receptor Potential Melastatin 3 (hTRPM3)* , 2003, Journal of Biological Chemistry.

[31]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[32]  M. Gladka,et al.  Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. , 2012, Journal of molecular and cellular cardiology.

[33]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.

[34]  F. T. ten Cate,et al.  Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. , 2009, JACC. Cardiovascular imaging.

[35]  L. McLain,et al.  Sudden death in young athletes. , 2003, Pediatric annals.